Integra LifeSciences to Buy Acclarent From Johnson & Johnson
By Colin Kellaher
Integra LifeSciences Holdings has agreed to buy ear, nose and throat (ENT) technology company Acclarent from a unit of Johnson & Johnson for $275 million in cash.
Integra on Wednesday said the deal, which expands its portfolio of ENT products and technologies, also includes an additional $5 million based on the achievement of certain regulatory milestones.
Princeton, N.J., medical-technology company Integra said Acclarent generated about $110 million in revenue in 2022.
Integra, which has forecast revenue of $1.54 billion to $1.55 billion for 2023, said it expects to complete the acquisition by the second quarter of 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 13, 2023 06:48 ET (11:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom